Linperlisib treatment for lymphoma in real-world practice
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well Linperlisib, a targeted drug, works for people with lymphoma in everyday medical care. It aims to provide real-world information about treatment effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of lymphoma.
- You must be willing to join the study and give written consent.
- Your doctor must agree that Linperlisib is a suitable treatment for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
This trial tests a new targeted therapy (linperlisib) combined with rituximab, an existing antibody drug, for people with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to previous treatments. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Focus on the Lymphoma Including B/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.